The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
UDP-glucuronosyltransferases and clinical drug-drug interactions
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease
Tukey, R. H., & Strassburg, C. P. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.581 · Cited by 1,523
Mackenzie, P. I., Owens, I. S., Burchell, B., Bock, K. W., Bairoch, A., Belanger, A., Gigleux, S. F., Green, M., Hum, D. W., Iyanagi, T., et al. (1997) · Pharmacogenetics · doi:10.1097/00008571-199708000-00001 · Cited by 1,183
Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., Koup, J. R., & Ball, S. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000794 · Cited by 928
Dresser, G. K., Spence, J. D., & Bailey, D. G. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038010-00003 · Cited by 908
Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K., & Hasegawa, Y. (2000) · PubMed · Cited by 783
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Iyer, L., Das, S., Janisch, L., Wen, M., Ramírez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., & Ratain, M. J. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500072 · Cited by 720
Update: Clinically Significant Cytochrome P‐450 Drug Interactions
Michalets, E. L. (1998) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03830.x · Cited by 597
Human UGT2B7 catalyzes morphine glucuronidation.
Coffman, B. L., Rios, G. R., King, C. D., & Tephly, T. R. (1997) · PubMed · Cited by 481
How Important Are Gender Differences in Pharmacokinetics?
Meibohm, B., Beierle, I., & Derendorf, H. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00002 · Cited by 454
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification
Rowland, A., Miners, J. O., & Mackenzie, P. I. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.02.019 · Cited by 709
PHASE II DRUG METABOLIZING ENZYMES
Jancova, P., Anzenbacher, P., & Anzenbacherova, E. (2010) · Biomedical Papers · doi:10.5507/bp.2010.017 · Cited by 603
Enzyme induction with antiepileptic drugs: Cause for concern?
Brodie, M. J., Mintzer, S., Pack, A. M., Gidal, B. E., Vecht, C. J., & Schmidt, D. (2013) · Epilepsia · doi:10.1111/j.1528-1167.2012.03671.x · Cited by 383
Impact of Obesity on Drug Metabolism and Elimination in Adults and Children
Brill, M. J. E., Diepstraten, J., van Rongen, A., van Kralingen, S., van den Anker, J. N., & Knibbe, C. A. J. (2012) · Clinical Pharmacokinetics · doi:10.2165/11599410-000000000-00000 · Cited by 382
Zhang, D., Chando, T. J., Everett, D. W., Patten, C. J., Dehal, S. S., & Humphreys, W. G. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005447 · Cited by 286
Bioavailability challenges associated with development of anti-cancer phenolics
Gao, S., & Hu, M. (2010) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955710791384081 · Cited by 242
Drug interactions evaluation: An integrated part of risk assessment of therapeutics
Zhang, L., Reynolds, K. S., Zhao, P., & Huang, S.-M. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.12.016 · Cited by 125
“A survey of 103 drugs that undergo glucuronidation showed that 78% were metabolized by UGT1A while 22% were by UGT2B isoforms (Kiang et al., 2005) (Drugs@FDA http://www.”
BackgroundInfluentialGallucci, G. M., Hayes, C. M., Boyer, J. L., Barbier, O., Assis, D. N., & Ghonem, N. S. (2024) · Cells · doi:10.3390/cells13151296 · Cited by 40
“In humans, hydrophobic molecules, e.g., bile acids, undergo glucuronidation catalyzed by UGT enzymes [38].”
BackgroundGallucci, G. M., Trottier, J., Hemme, C., Assis, D. N., Boyer, J. L., Barbier, O., & Ghonem, N. S. (2021) · Hepatology Communications · doi:10.1002/hep4.1787 · Cited by 26
Sun, D., Zhang, C.-Z., Ran, R.-X., Cao, Y.-F., Du, Z., Fu, Z.-W., Huang, C.-T., Zhao, Z.-Y., Zhang, W.-H., & Fang, Z.-Z. (2017) · Molecules · doi:10.3390/molecules22061008 · Cited by 15
“UGT-catalyzed glucuronidation reactions are responsible for about 35% of all drugs metabolized by phase II enzymes [27].”
Background
Metadata
- Authors
- KIANG, T., ENSOM, M., & CHANG, T.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2005-04
- Volume
- 106
- Issue
- 1
- Pages
- 97-132
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W1985410301
- Cited by
- 552
- References
- 127
- FWCI
- 19.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.